STOCK TITAN

BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BetterInvesting Magazine named Equifax (NYSE: EFX) and Neurocrine Bio (NASDAQ: NBIX) as "Stock to Study" for the May 2026 issue, urging investor research and education rather than buy recommendations.

The Editorial Advisory and Securities Review Committee highlighted fundamental data availability and called both companies worthy of further study for investors using the Stock Selection Guide.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – EFX

-1.55%
1 alert
-1.55% News Effect

On the day this news was published, EFX declined 1.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $198.45 Vol: Volume 1,246,101 is 0.67x...
low vol
$198.45 Last Close
Volume Volume 1,246,101 is 0.67x the 20-day average of 1,860,032 ahead of this article. low
Technical Shares traded below the 200-day MA, with price at 207.83 vs MA(200) of 232.73 before this news.

Peers on Argus

Momentum scanner only flagged DGNX moving down, with no directly related peers i...
1 Down

Momentum scanner only flagged DGNX moving down, with no directly related peers in the same consulting/analytics group, suggesting this feature article was more company-specific in focus than part of a broad sector move.

Historical Context

5 past events · Latest: Mar 03 (Neutral)
Pattern 5 events
Date Event Sentiment Move Catalyst
Mar 03 Conference participation Neutral +0.1% Announcement of attendance at three March 2026 investor conferences.
Feb 26 Management change Positive +0.5% Appointment of David Smith as President of U.S. Information Solutions.
Feb 25 Dividend increase Positive +4.9% Board approved 12% increase to $0.56 per-share quarterly dividend.
Feb 24 Market data update Neutral +2.0% Release of Market Pulse Q4 2025 U.S. consumer credit trends data.
Feb 17 Product launch Positive -0.1% Launch of Optimal Path credit score action plans in myEquifax app.
Pattern Detected

Recent news has mostly been operational and strategic updates, with modestly positive price reactions except for a flat response to the consumer app launch.

Recent Company History

Over the past few weeks, Equifax has reported several corporate developments. On Feb 17, it launched the Optimal Path credit-score tool in the myEquifax app with a slightly negative reaction. On Feb 24, Market Pulse data on $18.20 trillion in consumer debt coincided with a modest rise. A 12% dividend increase on Feb 25 drew the strongest positive move. Subsequent management and conference updates saw small gains. This educational magazine feature fits into that steady news flow.

Market Pulse Summary

This announcement highlights Equifax being selected as a “Stock to Study” by BetterInvesting Magazin...
Analysis

This announcement highlights Equifax being selected as a “Stock to Study” by BetterInvesting Magazine, alongside a review of another company from an undervalued perspective. It reinforces investor focus on fundamentals like sales, earnings, and profitability, without introducing new financial guidance. In context of recent dividend increases, product launches, and management changes, investors may track upcoming filings, earnings, and execution on strategy to gauge how fundamentals evolve from here.

Key Terms

nyse, nasdaq, stock selection guide
3 terms
nyse financial
"Equifax (NYSE: EFX) as worthy of further study"
A large, regulated marketplace where stocks and other securities are listed and traded, acting like a global auction house that matches buyers and sellers and helps determine share prices. It matters to investors because listing and trading there provide liquidity, price discovery, and regulatory oversight—making it easier to buy or sell holdings and giving companies a visible platform that can affect credibility and access to capital.
nasdaq financial
"Neurocrine Bio In. (NASDAQ: NBIX), which the independent"
The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.
stock selection guide financial
"using the Stock Selection Guide before making an investment decision."
A stock selection guide is a clear list of criteria and steps investors use to pick which company shares to buy, similar to a recipe or checklist that highlights important traits like price compared to earnings, expected growth, stability, and risk. It matters because it turns guesswork into a repeatable process, helping investors compare options, limit emotional choices, and make decisions aligned with their goals and risk tolerance.

AI-generated analysis. Not financial advice.

TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE: EFX) as worthy of further study and has named the company its "Stock to Study" for the May 2026 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Equifax's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=EFX.

A full report on Equifax will appear in the May 2026 issue of BetterInvesting Magazine. 

The same issue of BetterInvesting Magazine will also include a fundamental review of Neurocrine Bio In. (NASDAQ: NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn, Instagram and Facebook.

Contact: 877-275-6242

Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-equifax-inc-nyse-efx-and-neurocrine-bio-in-nasdaq-nbix-302707186.html

SOURCE NAIC-BetterInvesting

FAQ

What does BetterInvesting naming EFX as "Stock to Study" mean for investors?

It signals educational interest, not a buy recommendation. According to BetterInvesting, the designation invites investors to review Equifax fundamentals using the Stock Selection Guide before making decisions, offering consolidated metrics like sales, earnings, and return on equity for study and comparison.

When will the full BetterInvesting analysis of EFX and NBIX be published?

The detailed reviews will appear in the May 2026 issue. According to BetterInvesting, the magazine will include full fundamental reviews of Equifax (EFX) and Neurocrine Bio (NBIX) for investor education and further study.

Where can investors access the fundamental data for EFX referenced by BetterInvesting?

Investors can view consolidated metrics on the Stock Selection Guide website. According to BetterInvesting, the National Association of Investors Corp. provides one-page views of sales, earnings, pre-tax profit, and return on equity for EFX via the SSG link.

Does BetterInvesting endorse buying Equifax (EFX) or Neurocrine Bio (NBIX)?

No; the designation is for study and education only. According to BetterInvesting, securities mentioned are not endorsed or recommended for purchase and investors should perform their own analysis using the Stock Selection Guide.

Who selected EFX and NBIX as Stocks to Study for May 2026?

An independent Editorial Advisory and Securities Review Committee selected them. According to BetterInvesting, the committee—chaired by Doron P. Levin and including multiple CFA members—named Equifax and Neurocrine Bio worthy of further study.